drugset / Trial / NCT00324506
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
Phase 2
Completed
43 enrolled
University of Texas Southwestern Medical Center
Aspreva Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this safety/mechanistic study is to determine the safety and tolerability of oral Cellcept when compared with weekly intramuscular Avonex in relapsing multiple sclerosis. Safety will be assessed by virtue of changes in size and number of lesions on MRI scans.
Timeline
- Start
- 2006-05
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mycophenolate Mofetil | Small molecule | — | Oral |